Medication Class Introduction

Sphingosine-1-phosphate (S1P) receptor modulator medications are a class of targeted synthetic small molecule therapies introduced in the 2020s for the treatment of ulcerative colitis in appropriate patients.1–6 This class of medications targets S1P receptors, which regulate the migration of pro-inflammatory immune cells, primarily lymphocytes, from lymph nodes into the gut.3,4 By modulating this pathway, S1P receptor modulators may help reduce inflammation by lowering the number of circulating immune cells in the blood.

Targeted synthetic small molecule therapies are low-molecular-weight compounds that diffuse through cell membranes.4,5 Unlike biologic therapies such as monoclonal antibodies, which are large proteins usually administered by injection, targeted synthetic small molecules are typically administered orally and have a low risk of provoking immunogenicity.4

IBD Treatment Landscape2–4,7–14

IBD treatment landscape

JAK=Janus kinase; S1P=sphingosine-1-phosphate; TNF=tumor necrosis factor.

Role in IBD Pathogenesis

In inflammatory bowel disease (IBD), lymphocytes bearing S1P receptors exit lymph nodes via the efferent lymphatic vessels and enter the bloodstream, guided by the higher concentration of S1P in the lymphatic circulation and blood compared to the lymphoid tissue.4,15–18 As a result of this S1P gradient, lymphocytes egress and circulate, potentially infiltrating the gastrointestinal (GI) tract, which may contribute to the chronic inflammation seen in IBD.3,4,16,17

S1P receptor role in IBD pathogenesis

S1P=sphingosine-1-phosphate; S1PR=sphingosine-1-phosphate receptor.

Mechanism of Action in IBD

S1P receptor modulators (S1PRM), used in treating IBD, target S1P receptors on the plasma membrane of lymphocytes.3,4,19 By binding to these receptors, they induce receptor internalization and degradation, thereby preventing lymphocytes from sensing the S1P gradient.3,4,15–17,19 This blocks lymphocyte egress from the lymph nodes, resulting in fewer circulating lymphocytes in the bloodstream, and ultimately, leading to decreased inflammation and tissue damage.3,4,16,17,19

S1P receptor mechanism of Action in IBD

S1P=sphingosine-1-phosphate; S1PR=sphingosine-1-phosphate receptor; S1PRM=sphingosine-1-phosphate receptor modulator.

Resources

Current IBD Treatment Guidelines

Guidelines for managing IBD are available from the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA). You can access them through the following links:

Resources to Help Explain Medication Options for IBD to Patients

The Crohn’s & Colitis Foundation resources below may help you explain medication options, including the mechanism of action of IBD medication classes and how they are designed to work in the body, to your patients with IBD.

Resources to Help Understand Medical Management of IBD From UpToDate®

The UpToDate® resources below may help you understand medical management of IBD in adults including but not limited to disease activity, severity, and risk, as well as medication options for induction and maintenance.

For More Information on IBD Medications

To learn more about the medications commonly used to treat IBD—including potential side effects and safety considerations—please refer to the following resource:

Links to third-party websites are provided as resources and not intended to be an endorsement. Takeda is not responsible for their content.

  1. Imbrizi M, Magro F, Coy CSR. Pharmaceuticals (Basel). 2023;16(9):1272.
  2. Santiago P, Braga-Neto MB, Loftus EV Jr. Gastroenterol Hepatol (N Y). 2022;18(8):453-465.
  3. Choden T, Cohen NA, Rubin DT. Gastroenterol Hepatol (N Y). 2022;18(5):265-271.
  4. Pérez-Jeldres T, Tyler CJ, Boyer JD, et al. Front Pharmacol. 2019;10:212.
  5. Crohn’s & Colitis Foundation. Fact Sheet. October 2023. https://www.crohnscolitisfoundation.org/sites/default/files/2023-10/Targeted%20Synthetic%20Small%20Molecule%20Fact%20Sheet%20FINAL%2010.23_2.pdf. Accessed January 5, 2026.
  6. Shirley M. Drugs. 2024;84(2):247-254.
  7. Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Cochrane Database Syst Rev. 2020;8(8):CD000544.
  8. Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T. J Crohns Colitis. 2020;14(9):1316-1329.
  9. de Boer NKH, Peyrin-Biroulet L, Jharap B, et al. J Crohns Colitis. 2018;12(5):610-620.
  10. Lichtenstein GR, Loftus EV, Afzali A, et al. Am J Gastroenterol. 2025;120(6):1225-1264.
  11. Actis GC, Pellicano R, Fagoonee S, Ribaldone DG. J Clin Med. 2019;8(11):1970.
  12. Fudman DI, McConnell RA, Ha C, Singh S. Clin Gastroenterol Hepatol. 2025;23(3):454-469.
  13. Moschen AR, Tilg H, Raine T. Nat Rev Gastroenterol Hepatol. 2019;16(3):185-196.
  14. Martinez-Molina C, González-Suárez B. J Clin Med. 2025;14(11):3890.
  15. Peyrin-Biroulet L, Christopher R, Behan D, Lassen C. Autoimmun Rev. 2017;16(5):495-503.
  16. Becher N, Swaminath A, Sultan K. Ther Clin Risk Manag. 2022;18:913-927.
  17. Hanzel J, Hulshoff MS, Grootjans J, D’Haens G. Expert Rev Clin Immunol. 2022;18(5):513-524.
  18. Wang J, Goren I, Yang B, et al. Aliment Pharmacol Ther. 2022;55(3):277-291.
  19. Nielsen OH, Li Y, Johansson-Lindbom B, Coskun M. Trends Mol Med. 2017;23(4):362-374.

US-NON-11472v1.0 2/26